CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

Author:

Khanna Anchit12,Rane Jayant K.3,Kivinummi Kati K.14,Urbanucci Alfonso156,Helenius Merja A.1,Tolonen Teemu T.1,Saramäki Outi R.1,Latonen Leena1,Manni Visa1,Pimanda John E.2,Maitland Norman J.3,Westermarck Jukka78,Visakorpi Tapio1

Affiliation:

1. Prostate Cancer Research Center (PCRC), Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere and Tampere University Hospital, Tampere, Finland

2. Adult Cancer Program, The Prince of Wales Clinical School, Lowy Cancer Research Centre, UNSW Medicine, University of New South Wales, Sydney, Australia

3. YCR Cancer Research Unit, Department of Biology, The University of York, Heslington, United Kingdom

4. Department of Signal Processing, Tampere University of Technology, Tampere, Finland

5. Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway

6. Department of Cancer Prevention, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

7. Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland

8. Department of Pathology, University of Turku, Turku, Finland

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3